Victory Capital Management Inc. Has $153.26 Million Holdings in Medtronic plc (NYSE:MDT)

Victory Capital Management Inc. lessened its holdings in shares of Medtronic plc (NYSE:MDT - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,918,676 shares of the medical technology company's stock after selling 39,745 shares during the period. Victory Capital Management Inc. owned 0.15% of Medtronic worth $153,264,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new position in shares of Medtronic during the third quarter worth $27,000. Mainstream Capital Management LLC acquired a new position in Medtronic in the fourth quarter valued at $26,000. J. Stern & Co. LLP acquired a new position in Medtronic in the third quarter valued at $30,000. Stephens Consulting LLC lifted its holdings in Medtronic by 145.7% in the fourth quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company's stock valued at $27,000 after buying an additional 204 shares during the period. Finally, Fiduciary Advisors Inc. acquired a new position in Medtronic in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Insider Transactions at Medtronic

In other news, EVP Brett A. Wall sold 12,437 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the completion of the sale, the executive vice president now directly owns 40,979 shares of the company's stock, valued at $3,688,110. The trade was a 23.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.20% of the stock is currently owned by insiders.

Medtronic Trading Up 1.2 %

NYSE:MDT opened at $94.15 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. The firm has a 50-day moving average of $87.82 and a 200-day moving average of $87.68. The company has a market cap of $120.75 billion, a PE ratio of 28.62, a PEG ratio of 2.22 and a beta of 0.84. Medtronic plc has a one year low of $75.96 and a one year high of $95.57.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.36 by $0.03. The company had revenue of $8.29 billion during the quarter, compared to the consensus estimate of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. As a group, equities research analysts expect that Medtronic plc will post 5.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MDT shares. JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $99.00 to $96.00 and set a "neutral" rating on the stock in a report on Friday, November 15th. Barclays boosted their target price on shares of Medtronic from $105.00 to $109.00 and gave the company an "overweight" rating in a report on Tuesday, November 26th. Royal Bank of Canada restated an "outperform" rating and issued a $105.00 target price on shares of Medtronic in a report on Wednesday, February 19th. Needham & Company LLC restated a "hold" rating on shares of Medtronic in a report on Wednesday, February 19th. Finally, Wells Fargo & Company dropped their price objective on shares of Medtronic from $106.00 to $98.00 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Medtronic currently has an average rating of "Hold" and a consensus price target of $96.07.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.